NUTM2A and cancer: Future research should prioritize in vivo studies and clinical trials, leveraging emerging technologies such as CRISPR and single-cell RNA sequencing, to fully elucidate the therapeutic potential of targeting NUTM2A-AS1 in personalized cancer treatment.